Prior treatment with immunosuppressants among coronavirus disease 2019 (COVID‐19) inpatients at one hospital in Spain

Autor:	Adriana Martín-Fuentes, R Cabana‐Navia, Pablo Cobo-Rodríguez, Patricia González-Muñoz, María-Antonia Pastor-Nieto, E Jiménez‐Blázquez, Consuelo Sánchez-Herreros, J Martínez‐Mariscal, María-Elena Gatica-Ortega, Iván Checa-Recio, Miguel Torralba, Aránzazu Vergara-Sánchez, P. Checa‐Díaz, E. de Eusebio‐Murillo
Rok vydání:	2020
Předmět:	Male medicine.medical_specialty Coronavirus disease 2019 (COVID-19) medicine.medical_treatment Dermatology 030230 surgery Letter to Editor methotrexate corticosteroids 030207 dermatology & venereal diseases 03 medical and health sciences immunosuppressive 0302 clinical medicine Risk Factors COVID‐19 Cyclosporin a Internal medicine medicine Humans In patient Aged Immunosuppressant Prior treatment immunosuppression business.industry COVID-19 Immunosuppression Middle Aged anti‐TNF‐alpha medicine.disease Hospitals SARS‐Cov‐2 Hospitalization cyclosporin A Transplantation Infectious Diseases Spain Female Methotrexate Cytokine storm business Immunosuppressive Agents biological medicine.drug
Zdroj:	Journal of the European Academy of Dermatology and Venereology
ISSN:	1468-3083 0926-9959
DOI:	10.1111/jdv.16798
Popis:	Vulnerability to coronavirus disease 2019 (COVID‐19) in patients with cardiovascular risk factors is well known. However, the prognostic influence of immunosuppressive drugs or their ability to counteract the cytokine storm involving critically‐ill patients are uncertain. The scarce related literature mainly involves transplantation.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa5d1cf077b1820fde3194304933268d https://doi.org/10.1111/jdv.16798 Zobrazit plný text záznamu Plný text